Clinical Trials for Mesothelioma

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with advanced solid tumors or lymphomas, including molecularly defined cohorts such as ARID1A-mutant endometrial/ovarian clear cell and other solid tumors, BAP1-loss mesothelioma, PTCL/DLBCL (including EZH2-mutant), and mCRPC. Investigational therapy is tulmimetostat (CPI-0209), an oral dual EZH2/EZH1 inhibitor, given as monotherapy across cohorts and combined with enzalutamide in mCRPC.

ClinicalTrials.gov ID: NCT04104776

Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Previously Treated Mesothelioma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously treated diffuse pleural mesothelioma (post platinum/pemetrexed and/or immunotherapy) receive sacituzumab govitecan-hziy, a Trop-2–targeted antibody–drug conjugate delivering SN-38, with imaging-based response assessment by modified RECIST. Key eligibility includes measurable disease, ECOG 0 or KPS ≥70%, adequate organ function, and willingness for biopsies; notable exclusions include significant uncontrolled comorbidities and active uncontrolled viral infections.

ClinicalTrials.gov ID: NCT06477419

Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced, metastatic, or recurrent mesothelioma (epithelioid or biphasic with >80% epithelioid), or other solid tumors with high mesothelin expression (≥50% of tumor cells), who have progressed after standard therapies. Treatment involves lymphodepleting chemotherapy followed by a single infusion of autologous CAR T cells (TNhYP218) engineered to target a membrane-proximal epitope of mesothelin, using naive/stem cell memory T cells to potentially enhance efficacy.

ClinicalTrials.gov ID: NCT06885697

Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adults with unresectable, CD30-positive malignant mesothelioma (any site/histology), previously treated or chemo‑naive, ECOG 0–2. Patients receive brentuximab vedotin IV every 21 days; this anti‑CD30 antibody-drug conjugate delivers MMAE to CD30-expressing cells, aiming for disease control with correlative biomarker analyses.

ClinicalTrials.gov ID: NCT03007030

Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with HRD-positive malignant mesothelioma (pleural, peritoneal, or tunica vaginalis) who are platinum-sensitive after prior cisplatin/carboplatin, ECOG 0–1, receive single-agent olaparib. Olaparib is an oral PARP1/2 inhibitor leveraging synthetic lethality in BAP1/HRR-deficient tumors; excludes prior PARP use and platinum-resistant disease.

ClinicalTrials.gov ID: NCT04515836

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease: A Phase I Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For adults (18–<80) with symptomatic, biopsy-proven pleural malignancy including pleural mesothelioma with pleural effusions refractory to available standard therapies and adequate performance status/organ function, this study tests locally manufactured autologous “Fast TILs” (pleural effusion–derived pleural-infiltrating T cells expanded ex vivo to enrich tumor-reactive T cells) given as a one-time intrapleural infusion after outpatient lymphodepleting chemotherapy. Patients then receive short-course low-dose intrapleural IL-2 to support T-cell activation and persistence.

ClinicalTrials.gov ID: NCT07192900

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors: A Phase I Trial (FAST TILS 2)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with symptomatic malignant pleural effusion from pleural mesothelioma or epithelial/mesothelial tumors metastatic to the pleura, refractory to standard therapies and with ECOG 0–1, receive outpatient lymphodepletion followed by intrapleural infusion of autologous pleural infiltrating T cells expanded ex vivo from their pleural fluid. Low-dose intrapleural IL-2 is given after cell infusion to support T-cell activation/persistence; the study primarily assesses manufacturing feasibility and safety with early signals of antitumor activity.

ClinicalTrials.gov ID: NCT07443020

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy in Patients with Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves patients with advanced or metastatic solid tumors, such as melanoma and non-small cell lung cancer, who have had prior therapies, evaluating the safety and efficacy of Alintegimod, an integrin-targeting agent, combined with ipilimumab and nivolumab.

ClinicalTrials.gov ID: NCT06362369

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with recurrent, unresectable, locally advanced, or metastatic solid tumors—including colorectal, pancreatic, NSCLC, ovarian cancer, mesothelioma, and others—that express mesothelin (MSLN) and have lost HLA-A*02 expression, who are heterozygous for HLA-A*02. Eligible patients receive a single infusion of A2B694, an autologous CAR T-cell therapy engineered with a logic-gated Tmod system to selectively target MSLN-positive, HLA-A*02-negative tumor cells.

ClinicalTrials.gov ID: NCT06051695

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients have advanced, unresectable, or metastatic solid tumors of multiple types that are refractory to standard therapy and have a tumor accessible for intratumoral injection or biopsy. This trial evaluates the investigational oncolytic immunotherapy VET3-TGI (a vaccinia-derived agent engineered to kill tumor cells and modulate the tumor microenvironment via CXCR3, IL-12, and TGF-β inhibition) given by intratumoral or intravenous administration, alone or with pembrolizumab.

ClinicalTrials.gov ID: NCT06444815